The groundbreaking fight against pancreatic cancer is seeing a progressive shift with the introduction of a personalized mRNA vaccine. The vaccine is currently under Phase 2 clinical trial by Memorial Sloan Kettering Cancer Center and utilizes the patient's immune system to combat unique cancer cells. The custom-made vaccine is formulated by identifying specific tumor mRNA sequences. These code for unique proteins or neoantigens. Once in the bloodstream, they train the immune system to identify and eradicate cells presenting these neoantigens. This innovative therapy was motivated by pancreatic cancer survivors and their tumors rich in immune cells. The tailored vaccine targets specific tumor proteins, potentially maximizing treatment success rates. The trial's promising results could make this standard treatment for various lethal cancers. Collaborative efforts and philanthropy have been key in advancing this research, highlighting the importance of continued investment.
Full article here: https://medium.com/@lawsuithelpdesk/title-revolutionizing-the-fight-against-pancreatic-cancer-the-unveiling-of-a-personalized-mrna-d94181fd3eba